Diabetes Research Institute, San Raffaele Scientific Institute

Last updated: 22.01.2016

logo-DRI

With the objective of reinforcing and expanding basic and clinical research on T1D, in late 2007 a specialized and independent research Institute – denominated Diabetes Research Institute (DRI) – was launched at San Raffaele. DRI is part of the International DRI federation (DRI-NET), which includes 12 other DRI’s around the world. The San Raffaele DRI is composed of six Units of Basic Research and five Groups of Clinical Research.

The overall objective of DRI is to prevent and cure T1D. To achieve this objective, two specific programs are pursued, both of which take advantage of patients and animal models:

  1. Prediction and prevention of T1D: aims at defining pathogenetic mechanisms of induction and perpetuation of autoimmunity and developing strategies for halting/reverting the progression to T1D.
  1. Beta cell replacement and cell therapy in T1D: aims at developing novel immune tolerance-inducing, immunosuppression-lightening and islet-regeneration therapies to prolong the survival of native and/or transplanted beta cells.

Contact

San Raffaele Hospital – Milan, via Olgettina 60, 20132 Milan, Italy

Tel. 02 26 431

Related

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here